Synonym
GS-9667; GS-9667; GS-9667; CVT 3619.
IUPAC/Chemical Name
(2S,3S,4R,5R)-2-(((2-fluorophenyl)thio)methyl)-5-(6-(((1R,2R)-2-hydroxycyclopentyl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
InChi Key
IZRXENCTXNMAMI-DIJFLQFKSA-N
InChi Code
InChI=1S/C21H24FN5O4S/c22-11-4-1-2-7-15(11)32-8-14-17(29)18(30)21(31-14)27-10-25-16-19(23-9-24-20(16)27)26-12-5-3-6-13(12)28/h1-2,4,7,9-10,12-14,17-18,21,28-30H,3,5-6,8H2,(H,23,24,26)/t12-,13-,14-,17-,18-,21-/m1/s1
SMILES Code
c1ccc(c(c1)F)SC[C@@H]2[C@H]([C@H]([C@@H](O2)n3cnc4c3ncnc4N[C@@H]5CCC[C@H]5O)O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
461.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L. Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92. doi: 10.1002/jcph.9. Epub 2013 Feb 20. PubMed PMID: 23427000.
2: Yang M, Chu R, Chisholm JW, Doege H, Belardinelli L, Dhalla AK. Adenosine A₁ receptors do not play a major role in the regulation of lipogenic gene expression in hepatocytes. Eur J Pharmacol. 2012 May 15;683(1-3):332-9. doi: 10.1016/j.ejphar.2012.03.012. Epub 2012 Mar 16. PubMed PMID: 22449383.
3: Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther. 2009 Jan;328(1):306-11. doi: 10.1124/jpet.108.143594. Epub 2008 Oct 24. PubMed PMID: 18952888.
4: Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab. 2009 Feb;11(2):95-101. doi: 10.1111/j.1463-1326.2008.00902.x. Epub 2008 May 20. PubMed PMID: 18494808.
5: Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab. 2007 May;292(5):E1358-63. Epub 2007 Jan 16. PubMed PMID: 17227958.
6: Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther. 2007 Apr;321(1):327-33. Epub 2007 Jan 4. PubMed PMID: 17204748.
7: Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, Shryock JC. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther. 2006 May;317(2):676-84. Epub 2006 Jan 12. PubMed PMID: 16410404.
